Marvel Biosciences Corp (TSE:MRVL)
:MRVL
Top Page
Marvel Biosciences Corp
(MRVL)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.16
▲(16.43% Upside)
Action:ReiteratedDate:04/08/26
The score is weighed down primarily by weak financial performance (no revenue, ongoing losses, negative equity, and continued cash burn). Technicals are moderately supportive in the near term (price above key short/mid-term averages with neutral momentum), but valuation remains constrained due to negative earnings and no dividend yield.
Positive Factors
Improving cash burn
Reported improvement in cash burn and year-over-year free cash flow direction indicates the company is trimming outflows and becoming more efficient. Sustained reduction in burn meaningfully extends runway and reduces near-term refinancing pressure, improving strategic optionality.
Negative Factors
Pre-revenue status
No revenue means the company lacks commercial validation and depends entirely on external funding to sustain operations. This structural profile increases execution risk, lengthens time-to-value, and makes long-term viability contingent on successful trials or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash burn
Reported improvement in cash burn and year-over-year free cash flow direction indicates the company is trimming outflows and becoming more efficient. Sustained reduction in burn meaningfully extends runway and reduces near-term refinancing pressure, improving strategic optionality.
Read all positive factors
Marvel Biosciences Corp (MRVL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.86M
Dividend YieldN/A
Average Volume (3M)89.38K
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees5
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding58,004,482
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Marvel Biosciences Corp Business Overview & Revenue Model
Company Description
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The c...
How the Company Makes Money
null...
Marvel Biosciences Corp Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -250.94K | -547.37K | 0.00 | -887.52K | -1.38M | -613.10K |
| EBITDA | -1.81M | -1.94M | -1.54M | -2.25M | -2.55M | -1.25M |
| Net Income | -2.09M | -2.21M | -1.65K | -2.29M | -2.55M | -3.04M |
Balance Sheet | ||||||
| Total Assets | 319.62K | 326.71K | 491.31K | 672.39K | 913.54K | 2.47M |
| Cash, Cash Equivalents and Short-Term Investments | 274.17K | 128.85K | 345.77K | 556.62K | 593.21K | 2.39M |
| Total Debt | 2.31M | 2.31M | 1.71M | 1.00M | 0.00 | 0.00 |
| Total Liabilities | 4.18M | 4.33M | 3.32M | 2.39M | 718.00K | 112.48K |
| Stockholders Equity | -3.86M | -4.01M | -2.83M | -1.72M | 195.54K | 2.36M |
Cash Flow | ||||||
| Free Cash Flow | -1.47M | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M |
| Operating Cash Flow | -1.47M | -1.15M | -1.18M | -1.33M | -2.19M | -1.37M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 381.57K |
| Financing Cash Flow | 1.69M | 933.41K | 968.64K | 1.30M | 394.00K | 3.16M |
Marvel Biosciences Corp Technical Analysis
Positive
0.14
Price Trends
0.14
Positive
0.15
Positive
0.18
Negative
Market Momentum
<0.01
Negative
57.60
Neutral
70.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MRVL, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.14, and below the 200-day MA of 0.18, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.60 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MRVL.
Marvel Biosciences Corp Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
52 Neutral | C$9.11M | -6.03 | 19.14% | ― | ― | 62.43% | |
47 Neutral | C$9.86M | -6.62 | 64.41% | ― | ― | ― | |
47 Neutral | C$1.39M | -3.72 | -107.76% | ― | ― | 34.22% | |
44 Neutral | C$1.12B | -28.32 | -30.79% | ― | ― | -43.64% |
* Technology Sector Average
TSE:MRVL
Marvel Biosciences Corp
0.17
0.05
36.00%
TSE:BETR
BetterLife Pharma
0.06
-0.03
-33.33%
TSE:ENBI
Entheon Biomedical
0.10
-0.03
-23.08%
TSE:DRUG
Bright Minds Biosciences
113.99
71.42
167.77%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
Marvel Biosciences Corp Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial
Positive
Apr 7, 2026
Marvel Biosciences has secured financial and strategic backing from life sciences investor 5 Horizons Ventures to support its upcoming Phase I clinical trial of lead drug candidate MB-204. The partnership, which also involves CRO Novotech, is stru...
Business Operations and StrategyPrivate Placements and Financing
Marvel Biosciences Wins Alberta Funding to Advance MB-204 Into Phase I Trials
Positive
Mar 30, 2026
Marvel Biosciences Corp., a Calgary-based biotech developer of neurological and neurodevelopmental therapies, is advancing MB-204, a fluorinated derivative of Parkinson’s drug Istradefylline that targets the adenosine A2A receptor for potent...
Business Operations and StrategyProduct-Related Announcements
Marvel Biosciences Taps Novotech to Run Phase I Trial of Lead Neurodrug MB-204
Positive
Mar 25, 2026
Marvel Biosciences has appointed Australian firm Novotech as the contract research organization for the Phase I clinical trial of its lead drug candidate MB-204, a neuroactive adenosine A2A antagonist for neurodevelopmental disorders. Leveraging A...
Business Operations and StrategyProduct-Related Announcements
Marvel Biosciences Wins Key U.S. Patent for Lead Neurology Drug MB-204
Positive
Mar 18, 2026
Marvel Biosciences Corp. has been granted a U.S. composition of matter patent for its lead therapeutic candidate MB-204, covering purine compounds for treating disorders and marking the third major jurisdiction to protect the molecule after Japan ...
Business Operations and Strategy
Marvel Biosciences Backs European Purine Meeting to Bolster A2A Neurology Strategy
Positive
Mar 4, 2026
Marvel Biosciences Corp. has been named a platinum-level sponsor of the 3rd European Purine Meeting in Bordeaux, France, scheduled for June 30 to July 3, 2026, an event that convenes global experts to advance research on the purinergic system and ...
Business Operations and StrategyExecutive/Board Changes
Marvel Biosciences Grants Deferred Share Units to Independent Directors
Positive
Feb 18, 2026
Marvel Biosciences Corp. has granted 50,001 deferred share units to its three independent directors in lieu of cash fees, aligning board compensation more closely with shareholder interests. The units, valued using the volume-weighted average pric...
Business Operations and StrategyProduct-Related Announcements
Marvel Biosciences Wins NRC IRAP Support for Pediatric Liquid Form of Lead Neurodrug
Positive
Feb 18, 2026
Marvel Biosciences Corp. has secured advisory services and funding from Canada’s National Research Council Industrial Research Assistance Program to develop a pediatric-friendly liquid formulation of its lead compound, MB-204. The initiative...
Business Operations and Strategy
Marvel Biosciences Wins Key Japanese Patent for Lead Neurology Drug MB-204
Positive
Feb 3, 2026
Marvel Biosciences Corp. has secured a Japanese composition-of-matter and methods-of-use patent for its lead therapeutic candidate MB-204, marking Japan as the second major jurisdiction to grant such protection for the molecule. The new patent str...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.